Mirtazapine updated on 07-01-2025

Child/Infant death (> 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18444
R78325		 Lee (Controls exposed to SSRI), 2025 Infant death (29–365 days after birth) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 19.14 [0.38;971.37] C
excluded (control group) 		0/77   0/1,465 0 77
ref
S18417
R77894		 Lee (Controls unexposed, general pop), 2025 Infant death (29–365 days after birth) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 23.20 [1.43;376.35] C 0/77   130/463,440 130 77
ref
Total 1 studies 23.20 [1.43;376.35] 130 77
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Lee (Controls unexposed, general pop), 2025Lee, 2025 1 23.20[1.43; 376.35]130770%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, general pop;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 1 Tags Adjustment   - No  - No 23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 1 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 1 All studiesAll studies 23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 10.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18444

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale23.20[1.43; 376.35]13077 -NALee (Controls unexposed, general pop), 2025 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale19.14[0.38; 971.37]-77 -NALee (Controls exposed to SSRI), 2025 10.510.01.0